Indicaciones de la drospirenona más allá de la anticoncepción.

Autores:: Espitia De La Hoz, Franklin José

Tipo de recurso:: Article of journal

Fecha de publicación:: 2021

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_0e8f50290debb95e4c96b8a8c32745c6
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/13458
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Indicaciones de la drospirenona más allá de la anticoncepción.
dc.title.translated.eng.fl_str_mv	Indications of drospirenone beyond contraception.
title	Indicaciones de la drospirenona más allá de la anticoncepción.
spellingShingle	Indicaciones de la drospirenona más allá de la anticoncepción. Contraceptive agents Endometriosis Hyperandrogenism Menopause Progestins Premenstrual syndrome Anticonceptivos Endometriosis Hiperandrogenismo Menopausia Progestinas Síndrome premenstrual
title_short	Indicaciones de la drospirenona más allá de la anticoncepción.
title_full	Indicaciones de la drospirenona más allá de la anticoncepción.
title_fullStr	Indicaciones de la drospirenona más allá de la anticoncepción.
title_full_unstemmed	Indicaciones de la drospirenona más allá de la anticoncepción.
title_sort	Indicaciones de la drospirenona más allá de la anticoncepción.
dc.creator.fl_str_mv	Espitia De La Hoz, Franklin José
dc.contributor.author.spa.fl_str_mv	Espitia De La Hoz, Franklin José
dc.subject.eng.fl_str_mv	Contraceptive agents Endometriosis Hyperandrogenism Menopause Progestins Premenstrual syndrome
topic	Contraceptive agents Endometriosis Hyperandrogenism Menopause Progestins Premenstrual syndrome Anticonceptivos Endometriosis Hiperandrogenismo Menopausia Progestinas Síndrome premenstrual
dc.subject.spa.fl_str_mv	Anticonceptivos Endometriosis Hiperandrogenismo Menopausia Progestinas Síndrome premenstrual
publishDate	2021
dc.date.accessioned.none.fl_str_mv	2021-04-15 00:00:00
dc.date.available.none.fl_str_mv	2021-04-15 00:00:00
dc.date.issued.none.fl_str_mv	2021-04-15
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2021-3372
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2021-3372
identifier_str_mv	2215-7840 10.32997/rcb-2021-3372 2389-7252
url	https://doi.org/10.32997/rcb-2021-3372
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3372/2858
dc.relation.citationedition.spa.fl_str_mv	Núm. 2 , Año 2021
dc.relation.citationendpage.none.fl_str_mv	128
dc.relation.citationissue.spa.fl_str_mv	2
dc.relation.citationstartpage.none.fl_str_mv	120
dc.relation.citationvolume.spa.fl_str_mv	10
dc.relation.references.spa.fl_str_mv	Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004 Mar 31; 217(1-2): 255-61. https://doi.org/10.1016/j.mce.2003.10.030 Oelkers WH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric. 2005 Oct;8 Suppl 3: 19-27. https://doi.org/10.1080/13697130500330341 Stanczyk FZ. All progestins are not created equal. Steroids. 2003 Nov; 68(10-13): 879-90. https://doi.org/10.1016/j.steroids.2003.08.003 Stacy RA, Nelson AL. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot sudy. Am J Obstet Gynecol. 2013; 208(6): 499.e1-5. https://doi.org/10.1016/j.ajog.2013.02.013 Bhatia SC, Bhatia SK. Diagnosis and treatment of premenstrual dysphoric disorder. Am Fam Physician. 2002 Oct 1; 66(7): 1239-48. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003; 63(5): 463-92. https://doi.org/10.2165/00003495-200363050-00003 Benagiano G, Pera A, Primiero FM. The endometrium and hormonal contraceptives. Hum. Reprod. 2000; 15(1): 101–18. https://doi.org/10.1093/humrep/15.suppl_1.101 Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol. 2000 Mar; 13(3): 285-94. https://doi.org/10.1038/modpathol.3880050 Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003 Nov; 68(10-13): 891-905. https://doi.org/10.1016/j.steroids.2003.08.008 Duijkers IJ, Heger-Mahn D, Drouin D, Skouby S. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care. 2015; 20(6): 419-27. https://doi.org/10.3109/13625187.2015.1044082 Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015 Nov; 92(5): 439-44. https://doi.org/10.1016/j.contraception.2015.07.014 Duijkers IJM, Heger-Mahn D, Drouin D, Colli E, Skouby S. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016 Apr; 93(4): 303-309. https://doi.org/10.1016/j.contraception.2015.12.007 Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019 Dec; 98(12): 1549-1557. https://doi.org/10.1111/aogs.13688 Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015 Aug 27; 2015(8): CD011054. https://doi.org/10.1002/14651858.CD011054.pub2 Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013 Sep 12; 347: f5298. https://doi.org/10.1136/bmj.f5298 Rios LP, Ye C, Thabane L. Association between framing of the research question using the PICOT format and reporting quality of randomized controlled trials. BMC Med Res Methodol. 2010 Feb 5; 10:11. https://doi.org/10.1186/1471-2288-10-11 Ministerio de Salud y Protección Social. Resolución 8430 de 1993. Richter WH, Koytchev R, Kirkov V, Merki G, Colli E, Regidor PA. Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. Contraception. 2020 Feb; 101(2): 137-143. https://doi.org/10.1016/j.contraception.2019.10.005 Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013 Winter; 11(1): 41-7. https://doi.org/10.5812/ijem.4158 Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018 Oct 2; 9(77): 34628-34638. https://doi.org/10.18632/oncotarget.26015 White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006 Aug; 48(2): 246-53. https://doi.org/10.1161/01.HYP.0000232179.60442.84 Kodaman PH. Current strategies for endometriosis management. Obstet Gynecol Clin North Am. 2015 Mar; 42(1): 87-101. https://doi.org/10.1016/j.ogc.2014.10.005 Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014 Apr; 101(4): 927-35. https://doi.org/10.1016/j.fertnstert.2014.02.012 Taniguchi F, Enatsu A, Ota I, Toda T, Arata K, Harada T. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma. Eur J Obstet Gynecol Reprod Biol. 2015; 191: 116-20. https://doi.org/10.1016/j.ejogrb.2015.06.006 Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2007 Mar; 12(1): 30-5. https://doi.org/10.1080/13625180600983082 Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2006 Feb; 85(2): 436-40. https://doi.org/10.1016/j.fertnstert.2005.07.1311 Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004 Jun; 89(6): 2817-23. https://doi.org/10.1210/jc.2003-031158 van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002 Apr; 69(4 Suppl): 2-15. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD006586. https://doi.org/10.1002/14651858.CD006586.pub2 Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005 Dec; 72(6): 414-21. https://doi.org/10.1016/j.contraception.2005.08.021 Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005 Sep; 106(3): 492-501. https://doi.org/10.1097/01.AOG.0000175834.77215.2e Farrukh JB, Towriss K, McKee N. Abnormal uterine bleeding: Taking the stress out of controlling the flow. Can Fam Physician. 2015 Aug; 61(8): 693-7. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016 Jan; 214(1): 31-44. https://doi.org/10.1016/j.ajog.2015.07.044 Foidart JM, Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecol Endocrinol. 2007 Dec; 23(12): 692-9. https://doi.org/10.1080/09513590701582323 Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens. 2002 Sep; 15(9): 816-22. https://doi.org/10.1016/s0895-7061(02)02980-1 Bitzer J, Amy JJ, Beerthuizen R, Birkhäuser M, Bombas T, Creinin M, et al. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Eur J Contracept Reprod Health Care. 2013 Jun; 18(3): 143-7. https://doi.org/10.3109/13625187.2013.792637 Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul; 62(1): 29-38. https://doi.org/10.1016/s0010-7824(00)00133-5 Schweppe KW. The current place of progestins in the treatment of endometriosis. Expert Review of Obstetrics & Gynecology. 2012; 7(2):141–18. https://doi.org/10.1586/eog.11.71 Fainaru O, Linda C. Giudice, Johannes L. H. Evers, David L. Healy (eds): Endometriosis: Science and Practice: Wiley-Blackwell, Oxford, 2012, 600 pp, ISBN 978-1-4443-3213-1. J Obstet Gynaecol India. 2014 Jun; 64(3): 224–5. https://doi.org/10.1007/s13224-014-0565-9 Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag. 2008 Apr; 4(2): 487-92. https://doi.org/10.2147/tcrm.s6864 Rapkin AJ, McDonald M, Winer SA. Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder. Womens Health (Lond). 2007 Jul; 3(4): 395-408. https://doi.org/10.2217/17455057.3.4.395 Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000 Jun; 5(2): 124-34. https://doi.org/10.1080/13625180008500387 Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception. 2005 Jan; 71(1): 1-7. https://doi.org/10.1016/j.contraception.2004.07.010 Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric. 2007 Feb;10 Suppl 1: 3-10. https://doi.org/10.1080/13697130601114859 James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011 Oct; 158(2): 124-34. https://doi.org/10.1016/j.ejogrb.2011.04.025 American College of Obstetricians and Gynecologists. Committee Opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013; 121(4): 891–896. Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas. 2007 Aug 20; 57(4): 361-9. https://doi.org/10.1016/j.maturitas.2007.03.004 Chaikittisilpa S, Angsuwathana S, Chaovisitsaree S, Jirapinyo M, Wilawan K, Panyakhamlerd K, et al. Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. J. Med. Assoc. Thai. 2011, 94, 1019–1025.
dc.rights.spa.fl_str_mv	Franklin José Espitia De La Hoz - 2021
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Franklin José Espitia De La Hoz - 2021 https://creativecommons.org/licenses/by-nc-sa/4.0 http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3372
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/e47ab447-75b6-40ac-a381-294506785557/download
bitstream.checksum.fl_str_mv	67970955c01f9f99e5418bb32dcbffd7
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1814214227106201600
spelling	Espitia De La Hoz, Franklin José2021-04-15 00:00:002021-04-15 00:00:002021-04-152215-784010.32997/rcb-2021-33722389-7252https://doi.org/10.32997/rcb-2021-3372application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3372/2858Núm. 2 , Año 2021128212010Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004 Mar 31; 217(1-2): 255-61. https://doi.org/10.1016/j.mce.2003.10.030Oelkers WH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric. 2005 Oct;8 Suppl 3: 19-27. https://doi.org/10.1080/13697130500330341Stanczyk FZ. All progestins are not created equal. Steroids. 2003 Nov; 68(10-13): 879-90. https://doi.org/10.1016/j.steroids.2003.08.003Stacy RA, Nelson AL. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot sudy. Am J Obstet Gynecol. 2013; 208(6): 499.e1-5. https://doi.org/10.1016/j.ajog.2013.02.013Bhatia SC, Bhatia SK. Diagnosis and treatment of premenstrual dysphoric disorder. Am Fam Physician. 2002 Oct 1; 66(7): 1239-48.Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003; 63(5): 463-92. https://doi.org/10.2165/00003495-200363050-00003Benagiano G, Pera A, Primiero FM. The endometrium and hormonal contraceptives. Hum. Reprod. 2000; 15(1): 101–18. https://doi.org/10.1093/humrep/15.suppl_1.101Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol. 2000 Mar; 13(3): 285-94. https://doi.org/10.1038/modpathol.3880050Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003 Nov; 68(10-13): 891-905. https://doi.org/10.1016/j.steroids.2003.08.008Duijkers IJ, Heger-Mahn D, Drouin D, Skouby S. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care. 2015; 20(6): 419-27. https://doi.org/10.3109/13625187.2015.1044082Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015 Nov; 92(5): 439-44. https://doi.org/10.1016/j.contraception.2015.07.014Duijkers IJM, Heger-Mahn D, Drouin D, Colli E, Skouby S. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016 Apr; 93(4): 303-309. https://doi.org/10.1016/j.contraception.2015.12.007Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019 Dec; 98(12): 1549-1557. https://doi.org/10.1111/aogs.13688Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015 Aug 27; 2015(8): CD011054. https://doi.org/10.1002/14651858.CD011054.pub2Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013 Sep 12; 347: f5298. https://doi.org/10.1136/bmj.f5298Rios LP, Ye C, Thabane L. Association between framing of the research question using the PICOT format and reporting quality of randomized controlled trials. BMC Med Res Methodol. 2010 Feb 5; 10:11. https://doi.org/10.1186/1471-2288-10-11Ministerio de Salud y Protección Social. Resolución 8430 de 1993.Richter WH, Koytchev R, Kirkov V, Merki G, Colli E, Regidor PA. Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. Contraception. 2020 Feb; 101(2): 137-143. https://doi.org/10.1016/j.contraception.2019.10.005Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013 Winter; 11(1): 41-7. https://doi.org/10.5812/ijem.4158Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018 Oct 2; 9(77): 34628-34638. https://doi.org/10.18632/oncotarget.26015White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006 Aug; 48(2): 246-53. https://doi.org/10.1161/01.HYP.0000232179.60442.84Kodaman PH. Current strategies for endometriosis management. Obstet Gynecol Clin North Am. 2015 Mar; 42(1): 87-101. https://doi.org/10.1016/j.ogc.2014.10.005Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014 Apr; 101(4): 927-35. https://doi.org/10.1016/j.fertnstert.2014.02.012Taniguchi F, Enatsu A, Ota I, Toda T, Arata K, Harada T. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma. Eur J Obstet Gynecol Reprod Biol. 2015; 191: 116-20. https://doi.org/10.1016/j.ejogrb.2015.06.006Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2007 Mar; 12(1): 30-5. https://doi.org/10.1080/13625180600983082Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2006 Feb; 85(2): 436-40. https://doi.org/10.1016/j.fertnstert.2005.07.1311Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004 Jun; 89(6): 2817-23. https://doi.org/10.1210/jc.2003-031158van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002 Apr; 69(4 Suppl): 2-15.Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD006586. https://doi.org/10.1002/14651858.CD006586.pub2Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005 Dec; 72(6): 414-21. https://doi.org/10.1016/j.contraception.2005.08.021Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005 Sep; 106(3): 492-501. https://doi.org/10.1097/01.AOG.0000175834.77215.2eFarrukh JB, Towriss K, McKee N. Abnormal uterine bleeding: Taking the stress out of controlling the flow. Can Fam Physician. 2015 Aug; 61(8): 693-7.Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016 Jan; 214(1): 31-44. https://doi.org/10.1016/j.ajog.2015.07.044Foidart JM, Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecol Endocrinol. 2007 Dec; 23(12): 692-9. https://doi.org/10.1080/09513590701582323Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens. 2002 Sep; 15(9): 816-22. https://doi.org/10.1016/s0895-7061(02)02980-1Bitzer J, Amy JJ, Beerthuizen R, Birkhäuser M, Bombas T, Creinin M, et al. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Eur J Contracept Reprod Health Care. 2013 Jun; 18(3): 143-7. https://doi.org/10.3109/13625187.2013.792637Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul; 62(1): 29-38. https://doi.org/10.1016/s0010-7824(00)00133-5Schweppe KW. The current place of progestins in the treatment of endometriosis. Expert Review of Obstetrics & Gynecology. 2012; 7(2):141–18. https://doi.org/10.1586/eog.11.71Fainaru O, Linda C. Giudice, Johannes L. H. Evers, David L. Healy (eds): Endometriosis: Science and Practice: Wiley-Blackwell, Oxford, 2012, 600 pp, ISBN 978-1-4443-3213-1. J Obstet Gynaecol India. 2014 Jun; 64(3): 224–5. https://doi.org/10.1007/s13224-014-0565-9Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag. 2008 Apr; 4(2): 487-92. https://doi.org/10.2147/tcrm.s6864Rapkin AJ, McDonald M, Winer SA. Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder. Womens Health (Lond). 2007 Jul; 3(4): 395-408. https://doi.org/10.2217/17455057.3.4.395Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000 Jun; 5(2): 124-34. https://doi.org/10.1080/13625180008500387Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception. 2005 Jan; 71(1): 1-7. https://doi.org/10.1016/j.contraception.2004.07.010Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric. 2007 Feb;10 Suppl 1: 3-10. https://doi.org/10.1080/13697130601114859James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011 Oct; 158(2): 124-34. https://doi.org/10.1016/j.ejogrb.2011.04.025American College of Obstetricians and Gynecologists. Committee Opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013; 121(4): 891–896.Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas. 2007 Aug 20; 57(4): 361-9. https://doi.org/10.1016/j.maturitas.2007.03.004Chaikittisilpa S, Angsuwathana S, Chaovisitsaree S, Jirapinyo M, Wilawan K, Panyakhamlerd K, et al. Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. J. Med. Assoc. Thai. 2011, 94, 1019–1025.Franklin José Espitia De La Hoz - 2021https://creativecommons.org/licenses/by-nc-sa/4.0http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3372Contraceptive agentsEndometriosisHyperandrogenismMenopauseProgestinsPremenstrual syndromeAnticonceptivosEndometriosisHiperandrogenismoMenopausiaProgestinasSíndrome premenstrualIndicaciones de la drospirenona más allá de la anticoncepción.Indications of drospirenone beyond contraception.Artículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlePublicationOREORE.xmltext/xml2504https://repositorio.unicartagena.edu.co/bitstreams/e47ab447-75b6-40ac-a381-294506785557/download67970955c01f9f99e5418bb32dcbffd7MD5111227/13458oai:repositorio.unicartagena.edu.co:11227/134582024-09-05 15:30:47.907https://creativecommons.org/licenses/by-nc-sa/4.0Franklin José Espitia De La Hoz - 2021metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Indicaciones de la drospirenona más allá de la anticoncepción.

Publicaciones similares